Skip to main content
SpringerLink
Log in

Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3—A new tumor marker

  • Published:
Lung Aims and scope Submit manuscript

Abstract

We have tried to find a reliable panel of markers that would allow distinction between mesotheliomas and carcinomas metastatic to the pleura.

In a prospective study, we evaluated 54 pleural effusions: In 27 of the patients, a diagnosis of histologically proven metastatic carcinoma was subsequently established, 7 patients had biopsy-proven malignant mesotheliomas and 20 had benign, reactive effusions whose benign etiologies were established by more than 2 years clinical follow-up.

The MAb (monoclonal antibody) IOB3 proved to be diagnostic for carcinomas in all 27 cases (100%), whereas CEA (carcinoembryonic antigen) expression was found in only 22 out of 27 (81%). None of the malignant mesotheliomas, nor benign reactive mesothelial cells reacted with these two markers. All carcinomas, as well as one malignant mesothelioma, reacted with the MAb HEA125. Antibodies against 12 single cytokeratins, vimentin, and EMA (epithelial membrane antigen) were not helpful in the differentiation between malignant mesotheliomas and malignant carcinomatous pleural effusions. We conclude that adding the antibody IOB3 to the CEA assay should allow a reliable differentiation between these two entities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Blobel GA, Moll R, Franke WW, Kayser KW, Gould VE (1985) The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance. Am J Pathol 121: 235–247

    PubMed  CAS  Google Scholar 

  2. Bross KJ, Pangalis GA, Staatz C (1978) Demonstration of cell surface antigens and their antibodies by the peroxidase-antiperoxidase method. Transplantation 25: 331–334

    Article  PubMed  CAS  Google Scholar 

  3. Brown RW, Clark GM, Tandon AK, Allred DG (1993) Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol 24: 347–354

    Article  PubMed  CAS  Google Scholar 

  4. Churg A (1985) Immunohistochemical staining for vimentin and keratin in malignant mesothelioma. Am J Surg Pathol 9: 360–365

    Article  PubMed  CAS  Google Scholar 

  5. Cibas ES, Corson JM, Pinkus GS (1987) The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions. Hum Pathol 18: 67–74

    Article  PubMed  CAS  Google Scholar 

  6. Corsun JM, Pinkus GS (1982) Mesothelioma: Profile of keratin proteins and carcinoembryonic antigen. Am J Pathol 108: 80–87

    Google Scholar 

  7. Costabel U, Bross KJ, Matthys H (1985) The immunoperoxidase slide assay: A new method for the demonstration of surface antigens on bronchoalveolar lavage cells. Bull Eur Physiopathol Respir 21: 381–387

    PubMed  CAS  Google Scholar 

  8. Ghosh AK, Gatter KC, Dunnil MS, Mason DY (1987) Immunohistological staining of reactive mesothelium, mesothelioma, and lung carcinoma with a panel of monoclonal antibodies. J Clin Pathol 40: 19–25

    Article  PubMed  CAS  Google Scholar 

  9. Guzman J, Bross KJ, Costabel U (1990) Malignant pleural effusions due to small cell carcinoma of the lung. An immunocytochemical cell-surface analysis of lymphocytes and tumor cells. Acta Cytol 34: 497–501

    CAS  Google Scholar 

  10. Guzman J, Bross KJ, Würtemberger G, Costabel U (1989) Immunocytology in malignant pleural mesothelioma. Chest 95: 590–595

    Article  PubMed  CAS  Google Scholar 

  11. Holden J, Churg A (1984) Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma. Am J Surg Pathol 8: 277–279

    PubMed  CAS  Google Scholar 

  12. Jackson D, Waibel R, Weber E, Bell J, RA (1992) CD24, a signal-transducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas. Cancer Res 52: 5264–5270

    PubMed  CAS  Google Scholar 

  13. Joshi SS, DeBoer JM, Strandjord SJ, Pirrucello SJ, Sanger WG, Weisenburger DD, Sharp JG (1991) Characterisation of a newly established human Burkitt’s lymphoma cell line, OMA-BL-1. Intern J Cancer 47: 643–648

    Article  CAS  Google Scholar 

  14. Latza U, Niedobitek G, Sharting R, Nekarda H, Stein H (1990) Ber-EP4: New monoclonal antibody which distinguishes epithelia from mesothelia. J Clin Pathol 43: 213–219

    Article  PubMed  CAS  Google Scholar 

  15. Leong ASY, Stevens MW, Mukherjee TM (1992) Malignant mesothelioma: Cytologic diagnosis with histologic, immunohistochemical and ultrastructural correlation. Semin Diagn Pathol 9: 141–150

    PubMed  CAS  Google Scholar 

  16. McCaughey WTE (1985) Criteria for diagnosis of diffuse mesothelial tumours. Ann NY Acad Sci 132: 603–613

    Article  Google Scholar 

  17. Matsumura I, Tamaki T, Katagiri S, Taniwaki M, Tominaga N, Oritani K, Ilda M, Yagura H, Yonezawa T, Tarui S (1990) Establishment and characterization of a new human B-cell line (ONHL-1) from non-Hodgkin’s lymphoma: Constant expression of bcl-2 gene during mitogen-induced growth inhibition. Intern J Cancer 46: 1107–1111

    Article  CAS  Google Scholar 

  18. Moldenhauer G, Momburg F, Möller P, Schwartz R, Hämmereling GJ (1987) Epithelium specific surface glycoprotein of Mr 34.000 is a widely distributed human carcinoma marker. Br J Cancer 56: 714–721

    PubMed  CAS  Google Scholar 

  19. Moll R, Dhouailly D, Sun T-T (1989) Expression of keratin 5 as distinctive feature of epithelial and biphasic mesotheliomas. Virchows Archiv B Cell Pathol 58: 129–145

    Article  CAS  Google Scholar 

  20. Momburg F, Moldenhauer G, Hammerling GJ, Möller P. Immunohistochemical study of the expression of Mr 34000 human epithelium-specific surface glycoprotein in normal malignant tissues. Cancer Res 47: 2883–2891

  21. Mullink H, Henzen-Logmans SC, Alons-van Kordelaar JJM, Tadema TM, Meijer CJLM (1986) Simultaneous immunoenzyme staining of vimentin and cytokeratins with monoclonal antibodies as an aid in the differential diagnosis of malignant mesothelioma from pulmonary adenocarcinoma. Virchows Arch [Cell Pathol] 52: 55–65

    Article  CAS  Google Scholar 

  22. Nagasawa T, Nagasawa S (1984) Enrichment of malignant cells from pleural effusions of patients with malignant and non-malignant diseases. Cancer Lett 22: 1–9

    Article  Google Scholar 

  23. Ordoñez NG (1989) The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Am J Surg Pathol 13: 276–291

    PubMed  Google Scholar 

  24. Otis CN, Carter D, Cole S, Battifora H (1987) Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma. A bi-institutional study of 47 cases. Am J Surg Pathol 11: 445–456

    Article  PubMed  CAS  Google Scholar 

  25. Said JW, Nash G, Tepper G, Banks-Schlegel S (1983) Keratin proteins and carcino-embryonic antigen in lung carcinoma: An immunoperoxidase study of fifty-four cases, with ultrastructural correlations. Hum Pathol 14: 70–76

    Article  PubMed  CAS  Google Scholar 

  26. Sheibani K, Shin SS, Kezirian J, Weiss LM (1991) Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma. Am J Surg Pathol 15: 779–784

    Article  PubMed  CAS  Google Scholar 

  27. Silverman JF, Nance K, Phillips B (1987) The use of immunoperoxidase panels for the cytologic diagnosis of malignancy in serous effusions. Diagn Cytopathol 3: 134–140

    Article  PubMed  CAS  Google Scholar 

  28. Wang NS, Huang SN, Gold P (1979) Absence of carcinoembryonic antigen-like material in mesothelioma. Cancer 44: 937–943

    Article  PubMed  CAS  Google Scholar 

  29. Wick MR, Loy T, Mills SE, Legier JF, Manivel JC (1990) Malignant epitheliod pleural mesothelioma versus pulmonary adenocarcinoma: A histochemical, ultrastructural, and immunohistologic study of 103 cases. Hum Pathol 21: 759–766

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pneumologische Abteilung der Medizinischen Klinik, Universitätsklinik Freiburg, Hugstetter Strasse 55, 79106, Freiburg, Germany

    C. S. Kortsik, P. Werner, J. -C. Virchow, C. Kroegel, M. Pott & H. Matthys

  2. Pathologisches Institut der Universität Freiburg, Albertstrasse 19, 79104, Freiburg, Germany

    N. Freudenberg

Authors
  1. C. S. Kortsik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Werner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Freudenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. -C. Virchow
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Kroegel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Pott
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. Matthys
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kortsik, C.S., Werner, P., Freudenberg, N. et al. Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3—A new tumor marker. Lung 173, 79–87 (1995). https://doi.org/10.1007/BF02981468

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02981468

Key words

Search

Navigation